Stevens-Johnson syndrome future or investigational therapies
|
Stevens-Johnson syndrome Microchapters |
|
Differentiating Stevens-Johnson Syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Stevens-Johnson syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Stevens-Johnson syndrome future or investigational therapies |
|
FDA on Stevens-Johnson syndrome future or investigational therapies |
|
CDC on Stevens-Johnson syndrome future or investigational therapies |
|
Stevens-Johnson syndrome future or investigational therapies in the news |
|
Blogs on Stevens-Johnson syndrome future or investigational therapies |
|
Risk calculators and risk factors for Stevens-Johnson syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]
Overview
Certain agents have been used in the treatment of SJS/TEN, including cyclophosphamide and cyclosporine, among with cyclosporin has exhibited some therapeutic success. Intravenous immunoglobulin (IVIG) treatment has shown some promise in reducing the length of the reaction and improving symptoms
Future or Investigational Therapies
Multiple immunotherapies have been tried in patients with SJS and TEN and various studies are published but current data shows no clear benefit and further investigation is needed.
These include Plasmapheresis, Cyclophosphamide, TNF antagonists.
Recently, cycosporin has been under investigation as a potential treatment agent for patients with SJS/TEN. Some studies have shown positive effect, lower mortality and shorter time to re-epithelization upon use of cyclosporin in patients with TEN[1]. However, further studies are needed to confirm the drug efficacy in treatment of SJS/TEN
References
- ↑ Arévalo JM, Lorente JA, González-Herrada C, Jiménez-Reyes J (2000). "Treatment of toxic epidermal necrolysis with cyclosporin A." J Trauma. 48 (3): 473–8. PMID 10744287.